Neurotech International Limited (ASX:NTI)

Market Cap	19.44M
Revenue (ttm)	2.44M -23.1%
Net Income	-10.60M
EPS	-0.01
Shares Out	1.30B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,136,692
Average Volume	943,012
Open	0.0150
Previous Close	0.0150
Day's Range	0.0130 - 0.0150
52-Week Range	0.0120 - 0.0490
Beta	0.15
RSI	50.39
Earnings Date	Feb 24, 2026

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technolog...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In fiscal year 2025, Neurotech International's revenue was 2.44 million, a decrease of -23.07% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.